OCBC SecuritiesHomeSitemapContact Us
OCBC Investment Research
 
Oceanus Group Ltd: Poorer-than-expected FY09
 
Home >> Research
Oceanus Group Ltd: Poorer-than-expected FY09

By Lee Wen Ching
Fri, 26 Feb 2010, 09:56:30 SGT

Oceanus Group’s (Oceanus) FY09 results fell short of expectations. Sales gained 13.6% to RMB362.2m. Gains from fair value changes, which is reported as the group’s top line, grew 25.7% to RMB651.4m. Core net profit improved by 4.7% to RMB343.2m, but fell short of our RMB397.2m projection. Value of biological assets almost doubled to RMB831.0m on higher abalone prices and a higher proportion of larger sized abalones, reflecting the group’s efforts to sow future growth. In our view, Oceanus has an ambitious but hazy growth strategy. It needs to deliver convincing earnings growth before we can be assured of its growth strategy. We maintain our HOLD rating and reduce our fair value estimate to S$0.365.

FY09 results below expectations. Oceanus Group’s FY09 results came in below expectations. Sales gained 13.6% to RMB362.2m. Gains from fair value changes, which is reported as the group’s top line, grew 25.7% to RMB651.4m. Core net profit improved by 4.7% to RMB343.2m on high operating costs, but fell short of our RMB397.2m projection. The lower-than-expected figures were in part due to weak abalone prices experienced during the first nine months of 2009, which was an indirect result of the economic recession. We understand that abalone prices have since recovered on the back of an industry supply shortage caused by high mortality due to a prolonged summer and severe snow in Northern PRC. According to management, overall abalone valuations recovered by 40% in Dec 09 vs. Dec 08. As expected, no dividends were declared.

Fruits of labour starting to show in asset values. While the group’s earnings fell short of expectations, we were comforted that its NAV, which forms the basis of our valuation, rose 58% to 78.56 RMB cents per share, reflecting the group’s success in growing its biological assets in preparation for future growth. Value of biological assets almost doubled to RMB831.0m from RMB445.0m a year ago thanks to improved abalone prices, coupled with a higher proportion of larger sized abalones (the value of an abalone increases with its size). We believe that its expansion efforts should pay off in future when the group monetizes its assets either by selling in the live market or by processing its abalones.

Ambitious but hazy strategy. Population of caged abalones fell to 119.8m from 138.6m a year ago as Oceanus sold its young abalones even though they had not reached optimal values. This came as a surprise as we had expected Oceanus to sell its abalones only when they reached their optimal values after three years. We believe that the urgency to monetize its biological assets could have been driven by tank shortage. The group had originally targeted to expand to 40,000 tanks by Dec 09, but due to rising land costs, it has only managed 25,055 tanks. In our view, Oceanus has an ambitious but hazy strategy. It needs to deliver convincing earnings growth before we can be assured of its growth strategy. We maintain our HOLD rating on the stock and lower our fair value estimate to S$0.365 (from S$0.41).

 
Disclaimer for Research Report

This report is solely for information and general circulation only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our written consent. This report should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities mentioned herein. Whilst we have taken all reasonable care to ensure that the information contained in this publication is not untrue or misleading at the time of publication, we cannot guarantee its accuracy or completeness, and you should not act on it without first independently verifying its contents. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. You may wish to seek advice from a financial adviser regarding the suitability of the securities mentioned herein, taking into consideration your investment objectives, financial situation or particular needs, before making a commitment to invest in the securities. OCBC Investment Research Pte Ltd, OCBC Securities Pte Ltd and their respective connected and associated corporations together with their respective directors and officers may have or take positions in the securities mentioned in this report and may also perform or seek to perform broking and other investment or securities related services for the corporations whose securities are mentioned in this report as well as other parties generally.

Privileged/Confidential information may be contained in this message. If you are not the addressee indicated in this message (or responsible for delivery of this message to such person), you may not copy or deliver this message to anyone. Opinions, conclusions and other information in this message that do not relate to the official business of my company shall not be understood as neither given nor endorsed by it.


For and on behalf of OCBC Investment Research Private Limited:

Carmen Lee
Head of Research

Co.Reg.no.:198301152E



Print  Text Size
       Download Full Report
Home | Research | Market Pulse | Technical Analysis | Strategy | IPOs & Warrants | Sector | About Us
© Copyright 2007 - OCBC Investment Research.| All Rights Reserved | Co.Reg.no.:198301152E